Ultragenyx Earnings Call: Growth, Gene Therapy and Risk

Ultragenyx Pharmaceutical, Inc. ((RARE)) has held its Q1 earnings call. Read on for the main highlights of the call.

Ultragenyx Pharmaceutical’s latest earnings call struck an optimistic but cautious tone as management balanced strong commercial momentum and advancing gene therapy programs against heavy losses and cash burn. Executives emphasized reaffirmed 2026 guidance and a 2027 profitability goal, while acknowledging execution risks around upcoming launches, trial timing, and reliance on future voucher sales.

Q1 Revenue Base Led by Crysvita and Diversified Portfolio

Ultragenyx reported Q1 2026 revenue of $136 million, anchored by $93 million from Crysvita, with $39 million from North America, $46 million from Latin America and Turkey, and $8 million from Europe. Dojolvi and Evkeeza each contributed $18 million, while Mepsevii added $7 million, underscoring a still-narrow but growing rare-disease portfolio.

2026 Revenue Guidance Reaffirmed Despite Near-Term Volatility

Management reaffirmed full-year 2026 revenue guidance of $730 million to $760 million, implying 8% to 13% growth over 2025 and excluding any upside from new launches. The company framed this as a bridge toward scale, with Crysvita and Dojolvi expected to remain the core revenue engines as new therapies approach potential approval.

Evkeeza Delivers Standout Growth on Global Expansion

Evkeeza posted Q1 revenue of $18 million, up 64% versus the prior year’s quarter, driven by international launches and broader reimbursement. Management highlighted this trajectory as proof the company can ramp ultra-rare assets globally once access and distribution infrastructure are in place.

Global Commercial Footprint Extends Patient Reach

Ultragenyx now sells products in more than 35 countries, demonstrating scale unusual for a rare-disease specialist. Crysvita surpassed 950 patients in Latin America after about 30 new starts in Q1, while Dojolvi counts more than 675 reimbursed patients in North America and roughly 300 in Europe, and Evkeeza reaches about 370 patients across 18 countries.

Regulatory Catalysts: Two PDUFAs and a Pivotal Readout

Two potential near-term approvals are on deck, with DTX401 facing an August 23, 2026 PDUFA date and UX111 on September 19, 2026, with no advisory panel expected for DTX401. Meanwhile, the GTX-102 Aspire Phase 3 trial is slated for a top-line readout in the second half of 2026, alongside ongoing Aurora enrollment to broaden age and genotype coverage.

GTX-102 Long-Term Data Strengthen Angelman Thesis

In GTX-102’s Phase 1/2 program, 74 patients have been treated and 66 remain in long-term extension averaging about three years on therapy, with some followed for roughly five years. The Bayley-4 cognitive raw score improved by about 10 points at 12 months, beating the six-point threshold for meaningful change, while the Multi-domain Responder Index showed a p-value below 0.0001 over multiple time points.

Safety Profile and MDRI Endpoint Offer Promise and Risk

No new cases of transient lower extremity weakness were reported in the long-term GTX-102 data, supporting a favorable safety profile. However, while the MDRI endpoint has delivered statistically robust signals and has been agreed with regulators, its relatively nontraditional status leaves some residual regulatory and perception risk compared with classic single endpoints.

Manufacturing Ramp Positions Gene Therapies for Launch

The company is building inventory ahead of potential gene therapy launches, with its Bedford, Mass. facility now producing drug substance and product for DTX401 and performing fill-finish for UX111. Management framed this early ramp as essential to meet anticipated demand quickly if approvals arrive on schedule.

Cost Discipline and Multi-Year Expense Reset

Ultragenyx reiterated that combined R&D and SG&A spending in 2026 should be flat to down low single digits versus 2025, despite a growing pipeline and launch prep. By 2027, management targets at least a 15% reduction in combined R&D and SG&A compared with 2025, positioning expense control as a key driver of the path to profitability.

Priority Review Voucher Monetization Built Into the Model

The financial plan assumes the company will monetize two Priority Review Vouchers tied to UX111 and DTX401, modeled at just over $100 million each. Management noted that a potential additional voucher from GTX-102 would represent upside, but also cautioned that lower sale prices or timing slippage would pressure its profitability trajectory.

Cash Position and Seasonal Cash Usage Context

Ultragenyx ended Q1 with $534 million in cash, cash equivalents, and marketable securities, a level that management believes can bridge to key catalysts if spending moderates as planned. The company highlighted that the $197 million of operating cash use in the quarter was seasonally elevated by annual bonuses and some one-off payments.

Heavy Q1 Loss Highlights Need for Execution

The company posted a Q1 net loss of $185 million, or $1.84 per share, underscoring its dependence on future launches and voucher proceeds to extend runway. Management argued that operating cash burn should decline in later quarters, but investors remain highly focused on whether upcoming catalysts materialize on time and at scale.

High Operating Expenses and Restructuring Charges

Total operating expenses reached $305 million in Q1, including $30 million in cost of sales and $275 million in combined R&D and SG&A. The quarter also absorbed $30 million of non-cash stock-based compensation, $30 million tied to restructuring, $38 million in UX143 manufacturing payments, and $5 million in severance.

Profitability Hinges on PRVs and Launch Uptake

Management’s 2027 profitability roadmap depends heavily on successfully monetizing two Priority Review Vouchers and on strong uptake of upcoming launches. Any shortfall in voucher pricing, approval timing, or initial commercial traction could force Ultragenyx to revisit its expense plans or seek additional capital.

Uncertain Timing for GTX-102 Phase 3 Readout

The Aspire Phase 3 GTX-102 readout is only guided broadly to the second half of 2026, with no more precise timeline offered. Executives cited the complexity of international data unwinding and specialized endpoint assessments such as EEG as factors that could introduce variability in when data become available.

Study Burden and Real-World Access Considerations

Some discontinuations in the GTX-102 Phase 1/2 program were attributed to the burden of travel and site visits, not to drug-related safety issues. Management suggested these learnings could shape commercial strategies, as the company works to reduce access barriers once the therapy is, if approved, available outside the trial setting.

Crysvita Revenue Volatility Masks Steady Demand

Crysvita’s quarterly revenue continues to show lumpiness due to bulk ordering by government entities, particularly in Brazil, creating timing noise. Management stressed that underlying patient demand remains stable and growing, even if revenue recognition from large institutional orders can distort individual quarters.

Program-Level and Technical Risks in Earlier Pipeline

Ultragenyx acknowledged that the status of some early programs, including efforts in osteogenesis imperfecta, remains under evaluation, leaving uncertainty about which assets will move forward. In GNE myopathy, new prodrug designs aim to overcome past failures by improving muscle penetration, but prior disappointments highlight the technical risk until clear proof-of-concept emerges.

Guidance and Profitability Path Emphasize Growth with Discipline

Looking ahead, the company reaffirmed 2026 revenue guidance of $730 million to $760 million, including Crysvita at $500 million to $520 million and Dojolvi at $100 million to $110 million. Management reiterated its goal of achieving profitability in 2027 through a combination of mid-single-digit revenue growth, disciplined reductions in R&D and SG&A, and monetization of two Priority Review Vouchers, while potential launches of DTX401, UX111, and GTX-102 offer additional upside.

Ultragenyx’s earnings call painted a picture of a rare-disease specialist nearing a critical inflection point, with solid product growth and major gene therapy catalysts offset by sizable losses and execution risk. For investors, the story now hinges on whether the company can deliver approvals on time, monetize its vouchers at attractive levels, and translate its global footprint into sustainable profitability by 2027.